Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis , is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV
SVRA Stock | USD 3.31 0.05 1.49% |
About 61% of Savara's investor base is looking to short. The analysis of the overall investor sentiment regarding Savara Inc suggests that many traders are alarmed. The current market sentiment, together with Savara's historical and current headlines, can help investors time the market. In addition, many technical investors use Savara Inc stock news signals to limit their universe of possible portfolio assets.
Savara |
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episod
Read at businesswire.com
Savara Fundamental Analysis
We analyze Savara's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Savara using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Savara based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Savara is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Savara Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Savara stock to make a market-neutral strategy. Peer analysis of Savara could also be used in its relative valuation, which is a method of valuing Savara by comparing valuation metrics with similar companies.
Peers
Savara Related Equities
ALXO | Alx Oncology | 12.16 | ||||
ACLX | Arcellx | 8.69 | ||||
FENC | Fennec Pharmaceuticals | 2.97 | ||||
GPCR | Structure Therapeutics | 2.38 | ||||
TRDA | Entrada Therapeutics | 2.16 | ||||
RZLT | Rezolute | 1.19 | ||||
AVTE | Aerovate Therapeutics | 1.14 | ||||
XOMAO | XOMA | 0.39 | ||||
CRNX | Crinetics Pharmaceuticals | 0.33 | ||||
LBPH | Longboard Pharmaceuticals | 0.02 | ||||
STOK | Stoke Therapeutics | 0.33 | ||||
KZR | Kezar Life | 0.80 | ||||
TPST | Tempest Therapeutics | 1.04 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
ANAB | AnaptysBio | 2.32 | ||||
XOMA | XOMA Corp | 3.05 | ||||
DYN | Dyne Therapeutics | 4.34 | ||||
EWTX | Edgewise Therapeutics | 4.42 | ||||
XLO | Xilio Development | 4.59 | ||||
SRRK | Scholar Rock | 4.86 | ||||
RVMD | Revolution Medicines | 10.46 | ||||
TARA | Protara Therapeutics | 15.95 | ||||
PTIX | Protagenic Therapeutics | 20.34 |
Complementary Tools for Savara Stock analysis
When running Savara's price analysis, check to measure Savara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Savara is operating at the current time. Most of Savara's value examination focuses on studying past and present price action to predict the probability of Savara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Savara's price. Additionally, you may evaluate how the addition of Savara to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |